Kiromic BioPharma gibt Series E Vorzugsaktien im Rahmen eines Schuldenumtauschs aus Von Investing.com

Kiromic BioPharma, Inc. (OTCQB:KRBP), one of the biological products specialized in biotechnology, will probably be one of the most likely consequences for the treatment of some burdensome debts in self-capitalization.

In Houston, Texas, a loan agreement was entered into, a major debt settlement amounting to US$2.4 million that generated 3,000 Aktien worth of new Series E Convertible Voting Preferred Stock.

This transaction takes place on the Donnerstag, after the US Secretary of State of Delaware made a draft draft, the 6,000 Aktien were generated and no longer used as Series E Convertible Voting Preferred Stock. The new claim has a very high dividend rate of 25% and a normal incentive, the master stock is based on an as-if-converted basis.

Im Falle Einer Liquidation Des Unternehmens Oder Eines ähnlichen Ereignisses Haben Die Inhaber Der Serie E Preferred Stock Vorrang Bei Der Auszahlung Und Erhalten Den Höheren Betrag Einer Festgelegten Liquidations Ereignis in Stammaktien umwalked be true. The Series E Preferred Stock is available in the pedigree, based on a shell, which offers one of the best Formel options.

Kiromic BioPharma has identified one of the people the pathogen does not offend. This strategic financing is part of the financing of the internal economy, your capital structure and the operation of your management.

In other cases, the Lungenkrebsbehandlung Deltacel™ from Kiromic BioPharma from the US Food and Drug Administration (FDA) and the Fast-Track-Status can be performed. That regulatory Meilenstein soul is about the treatment and management of patients with metastatic small lung cancers (NSCLC), which is not based on the standard treatment, but which is not treated. Deltacel™ was found in a Phase 1 clinical trial, with Deltacel-01 targeting a patient with NSCLC in Stadium 4.

The Unternehmen have received financing of 2 million US dollars during the hiking debt settlements, as a strategic investment, and thus the capital for their operations. Kiromic BioPharma has a funded source of financing, repays US$7.2 million debt charges in equity and a new way to shift debt.

The results of the Delta Cell Phase 1 study for the treatment of metastasis of NSCLC in the stadium were 4 messages, with a patient experiencing a 6.6% reduction in tumor growth after treatment.

InvestingPro Insights

The young debt-own capital tauusch of Kiromic BioPharma mirrors the functioning of the external economies, their financial prospects for management, was intended to develop financing beyond what is relevant. Laut InvestingPro-Daten with a KRBP market capitalization of nur 2.16 million US dollars, was a small-cap status. Dieser Schritt, Debts get own capital from the tax, steht in Einklang with zwei wichtigen InvestingPro-Tipps: Das Unternehmen “work with a erheblichen Debtlast” and “verrennt schnell Bargeld”.

The separation, where you assume a certain dividend percentage of 25%, is a strange choice if a man considers that KRBP will give another InvestingPro tip “small dividend and the action” of stammaktien. This new proprietary asset manager can be used as a new capital injection.

Financial information from InvestingPro verdeutlichen de Situation von KRBP more. The company employs an operating business that has made its money with revenues of -22.34 million US dollars, while EBITDA is at -20.11 million US dollars. This period of unprofitable companies was no longer profitable, because the InvestingPro-Tipp had received a very good boost, because “the analysts did not expect the company to be profitable in those years”.

For investors, who make such an analysis, InvestingPro offers 15 other tips for KRBP, which support one of the financial prosperity and market position of their external economies.

This description can be performed by the intelligent intelligence. Weitere Informationen entnehmen Sie bitte unseren Nutzungsbedingungen.